Literature DB >> 32441504

In Situ Formation of Nanotheranostics to Overcome the Blood-Brain Barrier and Enhance Treatment of Orthotopic Glioma.

Haiyan Gao1,2, Chengchao Chu3, Yi Cheng3, Yang Zhang3, Xin Pang3, Dengfeng Li3, Xiaoyong Wang3, En Ren3, Fengfei Xie3, Yan Bai1,2, Lijuan Chen1,2, Gang Liu3, Meiyun Wang1,2.   

Abstract

Glioblastoma is one of the most lethal cancers and needs effective therapeutics. The development of coordination-driven metal-organic nanoassemblies, which can cross the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) and have multiple desired functions, may provide a promising solution to this issue. Here, we report an in situ assembled nanoplatform based on RGD peptide-modified bisulfite-zincII-dipicolylamine-Arg-Gly-Asp (Bis(DPA-Zn)-RGD) and ultrasmall Au-ICG nanoparticles. Attributed to its positive charges and neovascular targeting properties, Bis(DPA-Zn)-RGD can be selectively delivered to the tumor site, and then assembled in situ into large nanoclusters with subsequently administered Au-ICG nanoparticles. Au nanoparticles with ultrasmall size (∼7 nm) can successfully cross the BBB. The obtained nanoclusters exhibit strong near-infrared-red (NIR) absorption and an enhanced tumor retention effect, enabling precise orthotopic fluorescence/photoacoustic imaging. With the aid of image guidance, the photothermal effect of the nanoclusters is observed to suppress tumor progression with the inhibition efficiency reaching up to 93.9%. Meanwhile, no photothermal damage can be found for normal brain tissues. These results, herein, suggest a feasible nanotheranostic agent with the ability to overcome the BBB and BBTB for imaging and therapy of orthotopic brain tumors.

Entities:  

Keywords:  blood−brain barrier; nanocluster assembly; orthotopic glioma tumor; tumor microenvironment response; ultrasmall gold nanoparticles

Mesh:

Substances:

Year:  2020        PMID: 32441504     DOI: 10.1021/acsami.0c03873

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  8 in total

1.  Metal Ion-Based Supramolecular Self-Assembly for Cancer Theranostics.

Authors:  Bing Chen; Chengchao Chu; En Ren; Huirong Lin; Yang Zhang; Peiyu Wang; Hong Yao; Ailin Liu; Gang Liu; Xinhua Lin
Journal:  Front Chem       Date:  2022-05-20       Impact factor: 5.545

Review 2.  Nanomaterials for cancer therapy: current progress and perspectives.

Authors:  Zhe Cheng; Maoyu Li; Raja Dey; Yongheng Chen
Journal:  J Hematol Oncol       Date:  2021-05-31       Impact factor: 17.388

Review 3.  Think Big, Start Small: How Nanomedicine Could Alleviate the Burden of Rare CNS Diseases.

Authors:  Abdelfattah Faouzi; Valérie Gaëlle Roullin
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-30

4.  A nanotheranostic agent based on Nd3+-doped YVO4 with blood-brain-barrier permeability for NIR-II fluorescence imaging/magnetic resonance imaging and boosted sonodynamic therapy of orthotopic glioma.

Authors:  Zhijia Lv; Longhai Jin; Yue Cao; Hao Zhang; Dongzhi Xue; Na Yin; Tianqi Zhang; Yinghui Wang; Jianhua Liu; Xiaogang Liu; Hongjie Zhang
Journal:  Light Sci Appl       Date:  2022-04-29       Impact factor: 20.257

Review 5.  Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.

Authors:  Agata M Gawel; Ravi Singh; Waldemar Debinski
Journal:  Biomedicines       Date:  2022-07-05

6.  Biological activity of gold nanoparticles combined with the NFL-TBS.40-63 peptide, or with other cell penetrating peptides, on rat glioblastoma cells.

Authors:  A Griveau; C Arib; J Spadavecchia; J Eyer
Journal:  Int J Pharm X       Date:  2022-09-16

Review 7.  The Peptide Functionalized Inorganic Nanoparticles for Cancer-Related Bioanalytical and Biomedical Applications.

Authors:  Xiaotong Li; Minghong Jian; Yanhong Sun; Qunyan Zhu; Zhenxin Wang
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

Review 8.  Metal-Coordinated Supramolecular Self-Assemblies for Cancer Theranostics.

Authors:  Jiating Xu; Jun Wang; Jin Ye; Jiao Jiao; Zhiguo Liu; Chunjian Zhao; Bin Li; Yujie Fu
Journal:  Adv Sci (Weinh)       Date:  2021-06-18       Impact factor: 16.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.